Journalist

&
""
Latest by
Director Kim Young-bin of War of Kim and Terrorist Passes Away at 72
Director Kim Young-bin of 'War of Kim' and 'Terrorist' Passes Away at 72

영화 '김의 전쟁', '테러리스트' 등을 연출하며 1990년대 한국 영화계에 굵직한 자취를 남긴 김영빈 감독이 8일 별세했다. 향년 72세.8일 유족과 영화계에 따르면 고인은 이날 급환으로 세상을 떠났다.1955년생인 고인은 거장 임권택 감독의 연출부로 영화계에 발을 들였다. '씨받이'(1986), '아다다'(1987), '아제아제 바라아제'(1989) 등 한국 영화사에 남은 굵직한 명작들에서 조감독으로 활약하며 탄탄한 연출 내공을 쌓았다.이후 1992년 재일동포 김희로 사건을 모티브로 한 영화 '김의 전쟁'으로 정식 데뷔했다. 고인은 묵직한 사회적 메시지를 담아낸 이 데뷔작으로 제13회 청룡영화상 신인감독상, 제28회 백상예술대상 영화 부문 신인감독상 및 시나리오상, 제12회 한국영화평론가협회상 신인감독상 등 그해 주요 영화제 신인상을 석권하며 화려하게 비상했다.데뷔 이후에도 선 굵은 연출력을 바탕으로 활발한 작품 활동을 이어갔다. '비상구가 없다'(1993)를 비롯해 당대 최고의 흥행작으로 꼽히는 최민수 주연의 '테러리스트'(1995), '나에게 오라'(1996), '불새'(1996), '질주'(2007), '도시의 연애담'(2011) 등 다양한 장르를 오가며 관객들과 만났다.현장 연출 외에 영화계 발전에도 힘을 보탰다. 고인은 2011년과 2012년 부천국제판타스틱영화제(BIFAN) 집행위원장을 역임하며 영화제를 이끌기도 했다.고인의 빈소는 전남 고흥군 고흥읍 우주장례식장 3호실에 마련됐다. 발인은 오는 10일 오전 9시 엄수되며, 장지는 서울시립 추모공원이다.* This article has been translated by AI.

Renault Filante: The Ideal Travel Companion
Renault Filante: The Ideal Travel Companion

Renault's Filante is an excellent vehicle for travel. With its quiet driving experience and spacious interior, it is perfect for trips with a few friends and their luggage. It feels too good to be used solely for commuting. Over two days starting November 6, I drove approximately 400 kilometers between Seoul and Gangwon Province. The route included busy areas in downtown Seoul, highways, narrow alleys, and regular roads. Launched in March, the Filante is Renault's mid-size flagship crossover. The first thing that stands out about the Filante is its large body, typical of a mid-size vehicle. However, its elongated design with sharp angles gives it a sleek appearance. The sloping roofline towards the rear is also striking, appealing to those who prefer a distinctive look over a conventional one. Upon entering, the spaciousness is immediately noticeable. Even with the front passenger seat pushed back, the rear seats offer ample room. With two people in the front and one in the back, there is enough space for an overnight trip without needing to open the trunk. If more luggage is required, the rear seats can be folded down. The Filante's trunk has a base capacity of 633 liters, expandable to a maximum of 2050 liters. The quiet ride is another advantage as a travel companion. Throughout the drive, road shocks were barely felt. Both front and rear seat passengers enjoyed a comfortable experience. With the windows closed, external noise was minimal, allowing for easy conversation and creating a perfectly isolated space when music was played. The diverse infotainment options also make it a great choice for traveling with children. The large display features a built-in game called 'R: Racing,' which uses the actual road as the game background, making it feel like a shared driving experience. In 'R: Racing,' players earn points by overtaking other vehicles. The passenger display allows easy sharing of content with the central display by swiping left. Driving features can be finely adjusted. The regenerative braking intensity can be modified, affecting how much the vehicle slows down when the accelerator is released. Increasing the intensity results in a noticeable reduction in speed, while lowering it allows for a smoother glide. With passengers on board, reducing the braking intensity minimizes abrupt speed changes, making for a more comfortable drive. The driving assistance system makes it easier for even novice drivers to handle the large vehicle. When the 'Active Driver Assist' is activated, it automatically accelerates and decelerates according to the set speed and distance from the vehicle ahead. It also helps keep the car centered in its lane. The AI voice assistant 'A.Dot Auto' further reduces hassle while driving. Responding promptly to the command, "Hi Renault," A.Dot Auto efficiently operates the rear windows. This allows drivers to control key functions without reaching for the display, making it an attractive option for those with multiple passengers or children.* This article has been translated by AI.

Hana Securities Raises Target Price for Cosmecca Korea Amid Strong Growth
Hana Securities Raises Target Price for Cosmecca Korea Amid Strong Growth

Hana Securities announced on November 9 that it has raised its target price for Cosmecca Korea from 147,000 won to 155,000 won, citing strong growth in domestic operations, which saw a 55% increase compared to the same period last year despite a high base from the previous year. The investment recommendation remains a 'buy.'Park Jong-dae, a researcher at Hana Securities, stated in a report that "there has been a significant increase in orders from both large clients and small indie brands. Although there were fewer working days due to the Chuseok holiday and summer vacations, the company managed to handle the volume by increasing overtime and outsourcing." Park noted that Cosmecca Korea recorded consolidated sales of 247.5 billion won and an operating profit of 27.2 billion won in the third quarter, which fell short of market expectations but still demonstrated strong performance. He highlighted that domestic sales exceeded 200 billion won for the first time in a quarter, driving the improvement in results.When compared to the third quarter of 2021, sales have quadrupled, reflecting an average annual growth rate of 32%, significantly outpacing competitors such as Cosmax and Kolmar Korea during the same period.Regarding the profitability of domestic operations, Park analyzed that a temporary increase in costs had an impact. He explained, "The domestic operating profit margin declined compared to the previous quarter due to rising costs from increased outsourcing and a one-time incentive of about 2 billion won related to exceeding performance in the first half of the year." Additionally, he mentioned that "the issue of container shortages was resolved in the first half of the year," and projected that fourth-quarter domestic sales would likely be similar to those in the third quarter.* This article has been translated by AI.

Zolgensma cancer probe raises stakes for Korea and beyond
Zolgensma cancer probe raises stakes for Korea and beyond

ZURICH, November 08 (AJP) -A U.S. investigation into tumors linked to Zolgensma is raising questions about long-term monitoring for children in South Korea and worldwide who received the one-time gene therapy for a potentially fatal muscle-wasting disease. The findings also have implications for other treatments using similar technology. The U.S. Food and Drug Administration (FDA) said Friday it was reviewing whether stronger warnings or other regulatory action were needed, while maintaining that the benefits of Zolgensma and the related treatment Itvisma outweigh their potential risks for approved uses. For Korea, the findings put the focus on how children are followed after treatment and how emerging risks are explained to families. National health insurance has covered Zolgensma since August 2022, opening access to a treatment previously beyond the financial reach of most households. At the time, authorities set its reimbursed price at about 1.98 billion won per dose and said eligible patients would pay no more than 5.98 million won under the applicable out-of-pocket ceiling. Those figures describe the coverage terms announced in 2022. Korea’s monitoring requirements extend beyond the five-year treatment-response assessments associated with insurance coverage. When the Ministry of Food and Drug Safety approved Zolgensma in 2021, it designated the medicine for 15 years of follow-up for adverse events. The distinction matters: assessing whether a treatment works and tracking delayed safety problems serve different purposes. Made by Swiss drugmaker Novartis, Zolgensma treats spinal muscular atrophy (SMA), an inherited condition that destroys the nerve cells controlling muscles. Severe cases can rob babies of the ability to move, swallow and breathe. The therapy uses a modified viral carrier to deliver a functioning copy of the SMN1 gene. In the United States, it is administered as a single intravenous infusion to eligible children under two. Novartis said it had received nine reports of tumors among patients treated since the drug’s first approval in 2019. More than 6,000 patients have received Zolgensma through trials, access programs and commercial treatment. The reports do not establish that the medicine caused all nine tumors or provide a reliable measure of an individual patient’s risk. The FDA identified two cases in which the treatment’s viral DNA had inserted into the patients’ genome near or within GLI1, a gene capable of driving cancer. A third GLI1-associated case remains under investigation. The agency also said the risk applies to Itvisma because it uses the same viral carrier and genetic construct, although no tumors had been reported following that treatment. Itvisma is approved in the United States for patients aged two and older. The FDA is examining whether existing product warnings and follow-up studies adequately address the findings. It is also monitoring similar gene therapy programs, widening the implications beyond Novartis’s SMA treatments. For families, a central issue is what should change in their children’s care. In a November 4 update, England’s specialist Zolgensma team said the information then available did not warrant additional scans, tests or changes to routine follow-up. The FDA subsequently advised monitoring treated patients for tumor formation. These statements came from different authorities and do not establish a new Korean screening protocol. SMA Europe has urged Novartis to explain clearly what is known, what remains uncertain and whether additional monitoring is needed. Novartis said it had notified health authorities promptly and appropriately and was working with them on next steps. AJP Takeaways - The US Food and Drug Administration said on Friday it is investigating a “serious risk” of cancer linked to Zolgensma, Novartis’s one-time gene therapy for spinal muscular atrophy. - Novartis said it has received nine tumor reports in patients treated with Zolgensma since 2019, two of which showed evidence of a link to the gene therapy. - Zolgensma has been covered by South Korea’s national health insurance since August 2022, with Korean families required to agree to five years of follow-up checks. - Tags: Novartis, Zolgensma, Itvisma, US Food and Drug Administration, FDA, spinal muscular atrophy, gene therapy, GLI1, SMA Europe, Ministry of Food and Drug Safety, European Medicines Agency, Swissmedic, South Korea, national health insurance, Switzerland

Korean biotech firms tap European market at BIO-Europe
Korean biotech firms tap European market at BIO-Europe

ZURICH, November 08 (AJP) -Small and mid-sized South Korean drug developers are tapping the European market through BIO-Europe this week, seeking licensing deals with global pharmaceutical companies to bring their experimental medicines to patients worldwide. At least eight Korean firms will attend the three-day event opening Monday in Cologne, Germany. The gathering brings together more than 2,000 companies and investors from over 60 countries for about 30,000 one-on-one business meetings. For smaller developers, securing a global partner can help bridge the costly gap between a promising drug candidate and an approved medicine. Licensing agreements can provide funding and access to the clinical development, regulatory and sales networks needed to reach international markets. Now in its 32nd year, BIO-Europe offers Korean companies a chance to meet European drugmakers and investors face to face. Organizer Informa Connect says the event is expanding beyond dealmaking to address broader industry strategy, including regulation, manufacturing and financing. Korean developers arrive with some high-profile deals already behind them. ABL Bio licensed its brain drug-delivery technology to Britain’s GSK in April 2025 and to U.S. drugmaker Eli Lilly in November that year. In Cologne, ABL Bio will pursue further partnerships for the technology, called Grabody-B, which is designed to help medicines cross the blood-brain barrier — a protective layer that prevents many drugs from reaching the brain. It will also promote Grabody-T, its cancer immunotherapy platform designed to help the immune system attack tumors. D&D Pharmatech will continue licensing discussions for DD01, a once-weekly injection being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. In a U.S. mid-stage trial, 62.5 percent of patients receiving DD01 achieved resolution of MASH without worsening liver scarring, compared with 5.3 percent of those given a placebo. Rznomics, which already has a deal with Eli Lilly to develop a treatment for hereditary hearing loss, will seek partners for its ribonucleic acid (RNA) editing technology. It will also promote RZ-001, a drug candidate being developed for liver cancer and glioblastoma, an aggressive form of brain cancer. G2GBio will pitch GB-5001, a once-monthly injection intended as an alternative to daily doses of donepezil, a medicine used to treat symptoms of dementia. Other participants include Olix, which is developing RNA-based treatments for obesity and macular degeneration, an eye disease that can cause severe vision loss. Vigencell will present cell therapies for lymphoma, brain cancer and liver cancer, while Y-Biologics will promote its antibody-based cancer drug candidates. Pangen, a subsidiary of Huons Group, is seeking European partners for its biosimilar of erythropoietin (EPO), a medicine used to treat anemia. Biosimilars are medicines highly similar to existing biological drugs and can offer lower-cost treatment options. “We are expanding our biopharmaceutical business from emerging markets into developed countries based on our own core technology,” Pangen CEO Yoon Jae-seung said. Cologne is the latest stop in a busy year of overseas outreach for Korean biotech companies, following participation in BIO USA in San Diego in June and BIO Japan. The commercial goal is to turn those meetings into agreements that fund further development and establish a route to market. For smaller Korean firms, global partnerships can help advance their leading drug candidates while freeing resources for the next generation of treatments. AJP Takeaways - At least eight South Korean biotech firms, including ABL Bio, D&D Pharmatech and Rznomics, will seek licensing partners at BIO-Europe in Cologne, Germany, from November 9 to 11. - BIO-Europe brings together more than 2,000 companies and investors from over 60 countries for about 30,000 one-on-one partnering meetings, according to Korean media reports. - South Korean biotech companies have drawn growing global interest, with ABL Bio licensing its brain drug delivery technology to GSK and Eli Lilly in 2025. - Tags: BIO-Europe, South Korea, biotech, ABL Bio, D&D Pharmatech, Rznomics, G2GBio, Olix, Vigencell, Y-Biologics, Pangen, Hugel, Eli Lilly, GSK, Informa Connect, Cologne, licensing

South Koreas Stock Market Sees Largest Decline Among Major Economies Amid AI Concerns
South Korea's Stock Market Sees Largest Decline Among Major Economies Amid AI Concerns

◆아주경제 주요뉴스▷AI 外風에 가장 취약했다…韓증시 시총, 주요국 중 낙폭 1위- According to Bloomberg data, South Korea's stock market capitalization fell from $5.42 trillion on June 1 to approximately $3.60 trillion as of November 5, a decrease of about $1.44 trillion or 28.6%. This drop has caused South Korea to fall from sixth to ninth place in global stock market rankings.- The decline in South Korea's market capitalization is the largest among the top seven global markets. The significant drop is attributed to the country's heavy reliance on major semiconductor companies. In June, Samsung Electronics and SK Hynix both surpassed a market capitalization of $1 trillion, buoyed by a boom in AI memory semiconductors.- The situation has shifted due to changing investor sentiment surrounding the AI industry. Concerns over the profitability of investments following large-scale fundraising by major U.S. tech companies, along with potential regulatory tightening on data centers after the U.S. midterm elections, have emerged.- As the stock market plummets and investor sentiment worsens, South Korea's standing in the global asset market continues to decline. India, which lagged behind South Korea in June, has now surpassed it this month, along with the United Kingdom and Canada. As of November 5, the U.K.'s market capitalization stands at $4.04 trillion, exceeding South Korea's $3.60 trillion by $438 billion.◆주요 리포트▷美 중간선거가 보여준 데이터센터 지역사회 수용성 - The federal-level risk is not 'construction stoppage' but rather 'cost burden regulations,' which are likely to be implemented through state regulatory agencies rather than legislation.- Community demands from this election can be summarized into five main points: 1) Full utility cost burden (OH, IA) and prohibition of cost pass-through (NV), 2) Self-power procurement (NV) raises reliability issues, 3) Prohibition of evaporative cooling (NV) and water resource regulations (TX) address water issues, 4) Setback distances (IA) relate to noise issues, and 5) Prohibition of NDAs (TX, IA) and mandatory public hearings (IA) reflect transparency demands. In other words, voters are not asking for data centers to be built but rather for data centers to bear the externalized costs.- Until now, the environmental (E) and social (S) aspects of data centers have been considered non-financial metrics, but this election has shown that these non-financial metrics can lead to permitting and cost issues, ultimately impacting capital expenditure schedules and supply chain revenues.- Investors should focus not on 'how aggressive the Democrats are' but on how quickly data center operators can internalize community acceptance demands (costs related to fees, water, noise, transparency), as this speed is expected to influence South Korea's AI value chain. Ultimately, the reason this stock market adjustment is an ESG issue is that it suggests community acceptance has become a financial variable.◆펀드 동향(5일 기준, ETF 제외)국내주식형 3693억원해외주식형 -7284억원 ◆오늘(9일) 주요일정중국: 소비자물가지수(10월), 생산자물가지수(10월)독일: 수출입통계(9월)미국: 고용동향지수(10월)* This article has been translated by AI.

Union Divisions Over N% Performance Bonuses Intensify Labor Conflicts at Samsung
Union Divisions Over 'N% Performance Bonuses' Intensify Labor Conflicts at Samsung

As demands for performance bonuses linked to corporate profits spread across major manufacturing sectors, labor-management conflicts are becoming increasingly complex. Disputes over performance distribution among divisions have led to tensions not only between companies and labor unions but also among unions within the same company. Concerns are rising that expanding performance-based compensation could become a new source of conflict within the labor sector.According to a report released on November 8 by the Korea Employers Federation (KEF), labor disputes totaled 88 cases as of the end of September this year, a decrease from 99 cases during the same period last year. However, the number of lost workdays increased by 45.2%, rising from 336,800 days to 489,190 days.KEF identified the growing demand for 'N% performance bonuses,' which allocate a certain percentage of corporate profits to workers, as a key feature of this year's labor-management relations. This performance distribution model, highlighted by Samsung Electronics and SK Hynix, has spread to the automotive and shipbuilding industries. The Hyundai Motor union is demanding 30% of last year's net profit, while the HD Hyundai Heavy Industries union is seeking 30% of operating profit, and the HL Mando union is requesting 15% of operating profit as the basis for performance bonuses.The issue lies in the potential for conflicts among members due to the performance-based compensation system, which varies by division. A notable example is Samsung Electronics, where labor disputes over performance bonus criteria have escalated into conflicts between the Device Solutions (DS) division, responsible for semiconductors, and the Device Experience (DX) division, which handles smartphones and home appliances. As the DS division's performance improved, the gap in performance bonuses widened, prompting DX employees to demand equitable compensation and participate in protests.Recently, the establishment of a sixth labor union has introduced a new phase of conflict among unions. On November 4, the Ministry of Employment and Labor received a registration application for the 'Samsung Electronics Union Shop Labor Union.' This new union reportedly includes leaders from both the DS-focused super union and the DX-centered Donghaeng Union. Observers believe that internal conflicts within existing unions may have triggered the formation of this new union.If this trend spreads to other manufacturing sectors, it could further increase uncertainty in labor-management relations. In industries where the production processes are closely interconnected, such as automotive and shipbuilding, the profitability and wage payment capabilities of individual companies vary. If demands for performance distribution at specific workplaces influence wage negotiations at other companies, disparities in compensation standards across different workplaces could emerge as a new issue.KEF pointed out that conflicts at individual workplaces could also impact the production, sales, employment, and delivery schedules of partner companies. For instance, HL Mando has 292 partner companies in South Korea, employing approximately 40,000 people. If production at a key parts supplier halts, it could create burdens on wage negotiations across the entire industrial supply chain.Lee Kwang-ho, a senior member of the Labor Relations Support Team, stated, "Labor and management need to establish reasonable negotiation practices that comprehensively consider not only the short-term performance of individual companies but also the volatility of the industry, global competition, the need for future investments, and the impact on partner companies."* This article has been translated by AI.

Vances Allies Discourage Presidential Run, Suggest Governor Bid
Vance's Allies Discourage Presidential Run, Suggest Governor Bid

Following a defeat in the recent midterm elections, allies of Vice President JD Vance are reportedly discouraging him from running in the next presidential election, while Vance himself has yet to make a decision, according to a report by the Wall Street Journal on November 8.On election day, November 4, Vance received a text message from a longtime associate suggesting that he should not pursue a presidential bid. Some of Vance's political allies have expressed strong doubts about the Republican Party's chances of winning in two years, the newspaper reported.Two close associates even asked Vance about the possibility of returning to Ohio to challenge for a Senate seat, while one suggested he consider running for governor. Vance reportedly declined these proposals. It is unusual for a prominent presidential contender who has served as a senator and vice president to be advised to lower his political ambitions. The newspaper noted that the ease with which his associates made such suggestions is noteworthy.Additionally, Vance had anticipated the Republican Party's poor performance in the midterms. According to his associates, he has been pessimistic about the impact of the Iran war on the party's electoral prospects. In September, in response to a text from a political ally regarding the challenging political landscape for Republicans, Vance reportedly expressed uncertainty about whether he should run for president.Some donors have expressed disappointment over the Democratic Party's gain of a Senate seat in Vance's home state of Ohio. As a result, figures like Florida Governor Ron DeSantis are being mentioned as alternatives, the newspaper reported.Despite this, Vance remains a leading contender for the Republican nomination. Two of his associates told the WSJ that the midterm results reflect a rejection of President Donald Trump rather than a rejection of the party itself, suggesting that once the Iran war concludes, a pro-Trump coalition could be reestablished.After the midterm elections, Vance posted on social media platform X (formerly Twitter) highlighting four key issues: ending the Iran war, addressing inflation, emphasizing America First policies, and changing relations with Israel. Political consultant Douglas McKinnon noted in a column for The Hill that the Republican Party's midterm losses were due to rising living costs linked to the Iran war and a loss of support among workers and young voters. He pointed out that Vance, at 42 years old with four young children, is closer to Generation Z than most figures from the Trump administration.However, Politico reported that Vance faces the challenging task of appealing to voters by emphasizing his opposition to the Iran war while avoiding overt criticism of President Trump as he prepares for the next presidential election.

Interview: Kim Jae-won on His Role in Final Interview and Competing with Chii Kawa
Interview: Kim Jae-won on His Role in 'Final Interview' and Competing with 'Chii Kawa'

Actor Kim Jae-won, who has gradually built his filmography with roles in productions like 'Our Blues,' 'Eun-jung and Sang-yeon,' 'Lady Dua,' and 'Yumi's Cells 3,' is making his big-screen debut in the film 'Final Interview.' In the film, six candidates gather for a final interview, only to find mysterious envelopes containing each other's secrets, leading to suspicion and chaos. Kim portrays Han Jin-woo, a character with an altruistic nature, skillfully navigating the complexities of doubt and desperation. "I feel the happiest now that the movie is finally being released. I'm excited and nervous about how the audience will react. I'm really anxious because it's a project I put my all into," he said. The primary reason Kim chose 'Final Interview' was the escalating tension within a confined space. He also felt a connection to Han Jin-woo, who must maintain his composure amidst the chaos. "When I first received the script, I thought that if the tension in the interview room was well expressed, it could be a really interesting movie. During my first meeting with the director, he expressed a desire for me to play Han Jin-woo. After reading the script, I realized that Jin-woo's role was to keep his balance in the midst of confusion, which I felt I could do well," he explained. Kim found several similarities between himself and Han Jin-woo. He noted that he often comes across as calm and mature among his peers, which helped him understand the character better. "I didn't see much difference between my real personality and Jin-woo's. Even when I'm the youngest in a group, people don't usually see me as the youngest. I often hear that I seem a bit more mature, possibly because I've been socializing from a young age. Jin-woo has that same vibe, so I didn't feel he was a vastly different character," he said. The dynamic of six characters revealing their secrets and exchanging emotions created a theatrical tension for Kim. He approached each scene with the mindset of creating a performance together rather than just maintaining individual rhythms. "Personally, it felt like being seated together in a movie like 'Perfect Strangers.' I'm not sure if we can achieve that level of quality, but we all worked together with the mindset of performing a play," he said. To create the tension in the interview room, Kim drew from his own experiences. The anxiety and urgency he felt while preparing for college entrance exams served as a direct memory to understand Han Jin-woo's mindset during the final interview. "The most intense moment in my life was preparing for college entrance exams. I took the tension that Jin-woo feels in the interview room from my own experience during my college entrance interview. I tried to infuse that anxiety and urgency into my performance, and when things got tough, I would recall those moments to regain my emotions," he said. His relationship with Jo Yi-hyun adds another layer of emotion to the film, filled with tension. On set, Jo's bright and lovely demeanor helped them bond naturally, which translated into their characters' relationship. "I had many scenes with Yi-hyun. Although she is older than me, she felt like a cute younger sister on set. She has a unique charm and lightens the mood when the cast is physically exhausted. So, even though I am younger in real life, I had no trouble portraying an older character. I think I was able to naturally incorporate the cuteness I felt from her into the performance," he said. However, it was crucial to balance their relationship to avoid it being perceived as overly romantic. They needed to build enough emotional depth to make Jin-woo and Hye-in's choices in the latter part of the film convincing without compromising the mystery's tension. "The main concern for me, the director, and Yi-hyun was to ensure that the mystery genre did not come off as a romance. We discussed how far to take Jin-woo and Hye-in's romantic narrative. We wanted to avoid it being too obvious or lacking in credibility, so we talked a lot about the characters and consulted during breaks," he said. The moment in the latter part of the film when Jin-woo casts his vote for Hye-in was the most challenging point for Kim to portray convincingly. He felt he would not have made the same decision in that situation, requiring him to deeply analyze the emotions and relationships of the character beyond the screen. "If I were in Jin-woo's situation, I don't think I could do that. So, I thought from the beginning that this was the most challenging aspect to portray convincingly. I wondered, 'How great must love be for someone to do that?' To play this role, I had to first acknowledge that choice, so I did a lot of character analysis that wasn't shown on screen. I also felt a sense of empathy for Jin-woo as a good person beyond love. We are the same age and in the same situation, desperately wanting to be chosen. Jin-woo is someone who dislikes seeing friendships break in that chaotic environment. Hye-in was both a colleague and someone he had a crush on, the person he trusted the most. So, I believe that voting for someone he could trust was the best choice Jin-woo could make," he said. His first experience on the big screen also provided him with a new perspective on acting. He learned that even small gestures are amplified on a larger screen, leading him to practice restraint and subtlety as filming progressed. "Seeing it on the big screen, I realized that even small actions feel much larger. I started to practice restraint as I monitored the filming. I think there are clear differences between film and drama. Through this project, I found film to be incredibly enjoyable, and I hope to work on more film projects in the future," he said. Another appealing aspect of the film set for him was the collaborative process of creating a scene with ample time for actors and staff. The lengthy rehearsals, adjustments to movements, and run-throughs left a strong impression of collective creation. "Unlike in dramas, I enjoyed gathering together for meals and discussing the next scenes. In dramas, there are many scenes to shoot, making it hard to have long rehearsals, but in film, even if we shoot one or two scenes a day, we do so with depth. The lengthy rehearsals and the process of running through the entire piece like a play, adjusting movements if something feels off, were enjoyable. It felt very collaborative, and I think that closeness is one of the charms of film," he said. As his filmography grows, Kim's criteria for choosing projects are evolving. Initially, he was grateful for any opportunity to be recognized and tried various roles, but now he is considering his responsibilities as an actor leading a project. "In the early stages of my career, I was so grateful for any opportunities that I tried everything. I had many chances to work with veteran actors in good projects. But now, I feel it's a time when I have a responsibility to lead a project. So, while the quantity of work is important, I want to focus more on the quality and deliver a more profound performance," he said. Kim identifies his strength as an actor as 'simplicity.' He believes that rather than having a strong, specific image, he can naturally blend into any role, which has allowed him to take on a variety of characters. "I think I have a certain simplicity as an actor. I've often been told that I have a face that can blend well with any role without feeling awkward. I believe that has allowed me to take on a relatively diverse range of roles since my debut," he said. Through his first screen debut, Kim has clear aspirations. He hopes for commercial success and aims to leave an impression that he has potential as an actor in film. He also wishes to showcase the strength of a fresh combination of young actors to the audience. "Honestly, I hope the film does well. And I hope that through this movie, I can show that Kim Jae-won is an actor with potential in film. I want this to be a work that demonstrates that there are many young actors and fresh combinations in the film industry. I want to beat 'Chii Kawa.' Haha," he said. * This article has been translated by AI.

Record Number of Foreign Tourists to South Korea, But Tourism Balance Shows Three-Month Deficit
Record Number of Foreign Tourists to South Korea, But Tourism Balance Shows Three-Month Deficit

Despite a record number of foreign tourists visiting South Korea this year, the tourism balance has recorded a deficit for three consecutive months. Although the deficit has decreased compared to the same month last year, the improvement has been shrinking each month since June. This trend is attributed to a slowdown in tourism revenue growth and an increase in domestic travelers' overseas spending.According to the Korea Tourism Organization's Korea Tourism Data Lab, the tourism balance for September was a deficit of $498 million. This is a 28.4% reduction from the deficit of $695.4 million in the same month last year, but it represents a deterioration of about $1.095 billion compared to the surplus of $596.6 million recorded in June.In June, tourism revenue increased by 50.0% compared to the same month last year, while tourism expenditures decreased by 19.0%, resulting in a significant surplus. However, in July, tourism revenue declined from the previous month while expenditures increased, leading to a return to a deficit.Although tourism revenue continued to grow, the rate of increase has slowed. The growth rate for the first half of the year was 36.4%, but it dropped to 24.3% in the third quarter. Monthly growth rates also fell from 50.0% in June to 16.4% in September. In contrast, tourism expenditures increased by 5.6% and 5.3% in August and September, respectively, compared to the same months last year.The improvement in the tourism balance compared to the same month last year also decreased from $1.4434 billion in June to $609 million in July, $410.1 million in August, and $197.4 million in September.In September, the number of visitors to South Korea increased by 21.1% compared to the same month last year, but tourism revenue only rose by 16.4%. Per capita tourism revenue, calculated by dividing total tourism revenue by the number of visitors, was $1,193, a 3.9% decrease from the same month last year. While the number of visitors increased, the decline in per capita tourism revenue meant that the overall growth rate in tourism revenue did not keep pace with the increase in visitors.Domestic travelers' overseas spending has been rising faster than the growth rate of outbound travelers. In September, the number of outbound travelers increased by 1.5% compared to the same month last year, while per capita tourism expenditures rose by 3.8%. The overall growth rate in tourism expenditures was 5.3%.Approximately 2.27 million people traveled abroad in September, about 200,000 more than the number of visitors to South Korea. Per capita tourism expenditures were $1,304, which was $111 more than per capita tourism revenue. In June, per capita tourism revenue exceeded expenditures by $306, but by September, expenditures surpassed revenue by $111.The cumulative tourism balance for this year has significantly improved compared to last year. From January to September, the deficit was $2.296 billion, a 70.9% decrease from the same period last year. Of the $5.3777 billion improvement, approximately 95% came from increased tourism revenue.However, there remains a considerable gap to achieve an annual surplus. To offset the cumulative deficit from January to September, an average monthly surplus of about $737 million is needed over the remaining three months. The largest monthly surplus this year was $596.6 million in June.Last year, the tourism balance for the fourth quarter was a deficit of $3.1731 billion. If a similar deficit occurs this year, the annual deficit would be approximately $5.383 billion, about half of last year's deficit of $10.7604 billion.Monthly tourism expenditures from October to December last year ranged from $2.7 billion to $3.2 billion. If overseas travel expenditures remain at similar levels this year, the increase in tourism revenue will determine whether the tourism balance improves in the fourth quarter.An industry insider noted, "While the number of visitors to South Korea has reached an all-time high, there is still a lack of tourism content that encourages longer stays and increased spending. Expanding products that promote longer stays and repeat visits, such as regional festivals and nighttime tourism, is essential for increasing tourism revenue."* This article has been translated by AI.